Evidence-based evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies.
Diagn. Cytopathol., Apr;38(4):252-9 (2010)
Diagnosis of metastatic neoplasms: a clinicopathologic and morphologic approach.
Arch. Pathol. Lab. Med., Feb;134(2):194-206 (2010)
Interobserver diagnostic variability at "moderate" agreement levels could significantly change the prognostic estimates of clinicopathologic studies: evaluation of the problem using evidence from patients with diffuse lung disease.
Ann Diagn Pathol., Apr;14(2):88-93 (2010)
World Health Organization classification of thymomas provides significant prognostic information for selected stage III patients: evidence from an international thymoma study group.
Hum. Pathol., Oct;41(10):1413-21 (2010)
The presence of isolated tumor cells and micrometastases in the intrathoracic lymph nodes of patients with lung cancer is not associated with decreased survival.
Hum. Pathol., Nov;41(11):1536-43 (2010)
Low cost-effectiveness of CD3/CD20 immunostains for initial triage of lymphoid-rich effusions: An evidence-based review of the utility of these stains in selecting cases for full hematopathologic workup.
Diagn. Cytopathol., Nov (2010)
A simplified Bethesda System for reporting thyroid cytopathology using only four categories improves intra- and inter-observer diagnostic agreement and provides non-overlapping estimates of malignancy risks.
Diagn. Cytopathol., May;40 Suppl 1:E62-8 (2012)
Missed diagnosis of limited ascending aortic dissection by multiple imaging modalities leading to fatal cardiac tamponade and aortic rupture.
Echocardiography., Oct;28(9):E187-90 (2011)
Evidence-based pathology and the pathologic evaluation of thymomas: transcapsular invasion is not a significant prognostic feature.
Arch. Pathol. Lab. Med., Jun;132(6):926-30 (2008)
Thymic epithelial neoplasms: a review of current concepts using an evidence-based pathology approach.
Hematol. Oncol. Clin. North Am., Jun;22(3):543-62 (2008)
Low cost-effectiveness of CD3/CD20 immunostains for initial triage of lymphoid-rich effusions: an evidence-based review of the utility of these stains in selecting cases for full hematopathologic workup.
Diagn. Cytopathol., Jul;40(7):565-9 (2012)
The application of special technologies in diagnostic anatomic pathology: is it consistent with the principles of evidence-based medicine?
Semin Diagn Pathol., May;22(2):156-66 (2005)
Mesothelioma in patients with nonoccupational asbestos exposure. An evidence-based approach to causation assessment.
Ann Diagn Pathol., Aug;10(4):241-50 (2006)
Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma.
Appl. Immunohistochem. Mol. Morphol., Jun;15(2):140-4 (2007)
Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
Arch. Pathol. Lab. Med., Mar;132(3):397-401 (2008)
Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma.
Cancer., Jun;112(12):2780-8 (2008)
What can we learn from the errors in the frozen section diagnosis of pulmonary carcinoid tumors? An evidence-based approach.
Hum. Pathol., Jan;40(1):1-9 (2009)
Lessons learned from mistakes and deferrals in the frozen section diagnosis of bronchioloalveolar carcinoma and well-differentiated pulmonary adenocarcinoma: an evidence-based pathology approach.
Am. J. Clin. Pathol., Jul;130(1):11-20; quiz 146 (2008)
The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis.
Hum. Pathol., Mar;40(3):356-65 (2009)
Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method.
Mod. Pathol., Jan;22(1):128-33 (2009)